ClinicalTrials.gg
CompletedNCT03790800INTERACT4Updated Mar 26, 2025

Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

A Phase 3 interventional study of urapidil in Stroke, Acute and Cerebrovascular Disorders, sponsored by The George Institute for Global Health, China. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by The George Institute for Global Health, China · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,425
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Enrollment
46th of 432
2,425 · median 169
Started
2020
with 22 others
Phase 3
62 of 613
16 open now
Registered
181st of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 46th largest by enrollment of the 432 interventional ones that give a count, is one of 23 that started in 2020, is one of 62 in phase 3, and was the 181st registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

A multicentre, ambulance-delivered, prospective, randomized, open-label, blinded endpoint (PROBE) study to assess the effects of hyperacute intensive blood pressure (BP) lowering initiated in ambulance setting on (i) functional outcome in patients with acute stroke (ii) safety in patients with confirmed acute stroke and other conditions that were initially suspected as acute stroke (i.e. stroke mimic).

Read the detailed description

As an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. INTERACT4 aims to evaluate the effects of functional outcome according to an ordinal analysis of the full range of scores on the mRS, the safety in all randomised patients; reperfusion treatment (thrombolysis and/or thrombectomy) related symptomatic ICH (sICH, according to standard definitions), infarct size, the time to and overall rate of reperfusion treatment in AIS patients; hematoma volume and early expansion in ICH.

03

Conditions studied

  • Stroke, Acute
  • Cerebrovascular Disorders

Keywords

  • stroke
  • blood pressure control
  • hypertension
  • clinical trial
  • ambulances
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥18 years;
  2. Acute syndrome that is due to presumed acute stroke, defined as FAST(Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit and time ≤2 hours from last seen well;
  3. Systolic BP ≥150
  4. Able to provide brief (if a waver of consent is not approved by the ethics committee)

Exclusion criteria

Exclusion Criteria:

  1. Coma - no response to tactile stimuli or verbal stimuli;
  2. Severe co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia,severe heart failure,pre-stroke disability[needed help]);
  3. History of epilepsy or seizure at onset;
  4. History of recent head injury (\<7 days);
  5. Hypoglycemia(glucose\<2.8mmol/L)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,425 participants (actual)

Study arms

  • Experimental
    Intervention group

    If systolic blood pressure\>180:IV Urapidil 25mg If systolic blood pressure\>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)

    Drug: urapidil

  • No intervention
    control group

    To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is \>220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.

Interventions

  • A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.

    Also known as: Intensive BP lowing

06

What researchers measure

Primary outcomes

  1. level of physical function

    Level of function defined across 7 categories of disability on the modified Rankin scale (mRS 0-6) in which scores of 0 or 1 indicate good function without or with symptoms but not disability, socress of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: Day 90

Secondary outcomes

  1. number of patients with serious adverse events

    total number of serious adverse events reported during follow-up, according to standard definitions

    Time frame: Day 90

  2. number of patients with any intracranial hemorrhage

    reperfusion treatment (thrombolysis/thrombectomy) related symptomatic intracerebral number of cases of intracranial hemorrhage, according to standard definitions

    Time frame: Day 7

  3. size of cerebral infarction

    overall size of cerebral infarction on MRI within 2 days in cases of ischaemic stroke

    Time frame: Day 2

  4. number of patients who receive reperfusion treatment

    total number of cases of reperfusion (thrombolysis and/or thrombectomy) in ischemic stroke

    Time frame: Day 0

  5. time to use of reperfusion treatment

    time from symptom onset to reperfusion treatment in patients with ischemic stroke

    Time frame: Day 0

  6. size of hematoma volume

    change in volume of hematoma from baseline to 24 hours, measured on brain imaging

    Time frame: Day 1

  7. size of hematoma volume

    volume of hematoma at baseline measured on brain imaging

    Time frame: Day 0

  8. death or major disability

    Level of function defined across 7 categories of disability on the modified Rankin scale (mRS 0-6) in which scores of 0 or 1 indicate good function without or with symptoms but not disability, socress of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death. mRS(3-6)

    Time frame: Day 90

  9. Death

    Time frame: Day 90

  10. Disability

    Level of function defined across 7 categories of disability on the modified Rankin scale (mRS 0-6) in which scores of 0 or 1 indicate good function without or with symptoms but not disability, socress of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: Day 90

  11. death or dependency measured by a shift in NIHSS

    Time frame: day 1 and day 7

  12. Health related quality of life

    according to the EQ-5D

    Time frame: day 90

07

Study locations

4 sites
  • The George Institute for Global Health
    Beijing, Beijing 100088, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200123, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
    Chengdu, Sichuan 610000, China
  • The First Affliated Hospital of Chengdu Medical College
    Chengdu, Sichuan 610500, China
08

References and documents

Publications

  • Song L, Chen C, Chen X, Guo Y, Liu F, Lin Y, Billot L, Li Q, Liu H, Si L, Ouyang M, Arima H, Bath PM, Ford GA, Robinson T, Sandset EC, Saver JL, Sprigg N, van der Worp HB, Zhang C, Yang J, Li G, Anderson CS; INTERACT4 investigators. INTEnsive ambulance-delivered blood pressure Reduction in hyper-ACute stroke Trial (INTERACT4): study protocol for a randomized controlled trial. Trials. 2021 Dec 6;22(1):885. doi: 10.1186/s13063-021-05860-y. PubMed 34872617 ↗

Individual participant data

Plan to share: Yes — Data will be shared with bona fide researchers after 1 year following conclusion of the study, based on a submitted protocol to the research office of The George Institute for Global Health, Sydney Australia

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 1 year after conclusion of the study

Access criteria: genuine researcher with supporting institution protocol review and approval by the research office of The George Institute

Data sharing details ↗ · georgeinstitute.org.au

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Nov 2023, 44 months.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 44 months is close to that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2018
First posted
Jan 2, 2019
StartActual
Mar 20, 2020
Primary completionActual
Nov 23, 2023
CompletionActual
Nov 30, 2023
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03790800
Lead sponsor
The George Institute for Global Health, China
Collaborators
Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
Responsible party
Craig Anderson (Director, Global Brain Health program, The George Institute for Global Health, China) — Principal investigator
First posted
Jan 2, 2019
Start date
Mar 20, 2020
Primary completion
Nov 23, 2023
Completion
Nov 30, 2023
Last update
Mar 26, 2025

Study contacts

Craig Anderson
principal investigator · The George Institute for Global Health, China
Lili Song
principal investigator · The George Institute for Global Health, China
Gang Li
principal investigator · Shanghai East Hospital, China
Jie Yang
principal investigator · Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
Yapeng Lin
principal investigator · The First Affliated Hospital of Chengdu Medical College, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urapidil

Start the discussion